Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Statera Biopharma, Inc. (STAB : NSDQ)

• Company Description    Statera BioPharma is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. Statera BioPharma, formerly known as Cytocom Inc., is based in FORT COLLINS, Colo. Number of Employees: 6

• Price / Volume Information    Yesterday's Closing Price: $0.24 Daily Weekly Monthly 20 Day Moving Average: 15,730,405 shares Shares Outstanding: 37.47 (millions) Market Capitalization: $9.06 (millions) Beta: 1.16 52 Week High: $7.10 52 Week Low: $0.20 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -18.20% -10.37% 12 Week -70.65% -68.16% Year To Date -89.49% -87.50%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2537 RESEARCH BOULEVARD SUITE 201 - FORT COLLINS,CO 80526 USA ph: 888-613-8802 fax: 716-849-6820 nichol.ochsner@staterabiopharma.com http://www.staterabiopharma.com

• General Corporate Information    Officers Christopher Zosh - Vice President of Finance Lea Verny - Director Randy Saluck - Director Alexander Andryushechkin - Director Anna Evdokimova - Director Peer Information Statera Biopharma, Inc. (CORR.) Statera Biopharma, Inc. (RSPI) Statera Biopharma, Inc. (CGXP) Statera Biopharma, Inc. (BGEN) Statera Biopharma, Inc. (GTBP) Statera Biopharma, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 857561104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/21 Next Expected EPS Date: - Share - Related Items Shares Outstanding: 37.47 Most Recent Split Date: 1.00 (0.05:1) Beta: 1.16 Market Capitalization: $9.06 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.10 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -1,075.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - - 12/31/21 - - 09/30/21 - -37.36 ROA 03/31/22 - - 12/31/21 - - 09/30/21 - -30.13 Current Ratio 03/31/22 - - 12/31/21 - - 09/30/21 - 1.31 Quick Ratio 03/31/22 - - 12/31/21 - - 09/30/21 - 1.31 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - -3,465.23 Book Value 03/31/22 - - 12/31/21 - - 09/30/21 - 2.31 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - - 12/31/21 - - 09/30/21 - 0.17 Debt-to-Capital 03/31/22 - - 12/31/21 - - 09/30/21 - 14.83

Powered by Zacks Investment Research ©